Get SEC filing alerts via email and in your feed for CERUS CORP
CERS
CERUS CORP
About CERUS CORP
Cerus Corporation develops and commercializes the INTERCEPT Blood System, a pathogen reduction technology designed to inactivate viruses, bacteria, parasites, and white blood cells in donated blood components such as platelets, plasma, and red blood cells. Serving blood centers, hospitals, and healthcare providers globally, Cerus aims to enhance blood safety by reducing transfusion-transmitted infections. Its business model relies on regulatory approvals, direct sales, and distributor partnerships across multiple international markets.
This description was generated via AI from an annual report.
Updated 8 months ago.